Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
Provided By GlobeNewswire
Last update: Nov 10, 2025
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital herpes –
Read more at globenewswire.com35.01
-0.26 (-0.74%)
Find more stocks in the Stock Screener
ASMB Latest News and Analysis
12 days ago - By: Chartmill
